Literature DB >> 25171726

Buprenorphine in the treatment of opioid addiction: opportunities, challenges and strategies.

Xiaofan Li1, Daryl Shorter, Thomas R Kosten.   

Abstract

INTRODUCTION: Buprenorphine follows the success of methadone as another milestone in the history of treatment for opioid addiction. Buprenorphine can be used in an office-based setting where it is clearly effective, highly accepted by patients and has a favorable safety profile and less abuse potential. However, the adoption of buprenorphine treatment has been slow in the USA. AREAS COVERED: This article first reviews the history of medication-assisted opioid addiction treatment and the current epidemic opioid addiction, followed by a review of the efficacy, pharmacology and clinical prescription of buprenorphine in office-based care. We then explore the possible barriers in using buprenorphine and the ways to overcome these barriers, including new formulations, educational programs and policy regulations that strike a balance between accessibility and reducing diversion. EXPERT OPINION: Buprenorphine can align addiction treatment with treatments for other chronic medical illnesses. However, preventing diversion will require graduate and continuing medical education and integrated care models for delivery of buprenorphine to those in need.

Entities:  

Keywords:  barriers; buprenorphine; integrated treatment model; office-based; opioid dependence

Mesh:

Substances:

Year:  2014        PMID: 25171726     DOI: 10.1517/14656566.2014.955469

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  12 in total

Review 1.  The Role of Behavioral Interventions in Buprenorphine Maintenance Treatment: A Review.

Authors:  Kathleen M Carroll; Roger D Weiss
Journal:  Am J Psychiatry       Date:  2016-12-16       Impact factor: 18.112

2.  Barriers Rural Physicians Face Prescribing Buprenorphine for Opioid Use Disorder.

Authors:  C Holly A Andrilla; Cynthia Coulthard; Eric H Larson
Journal:  Ann Fam Med       Date:  2017-07       Impact factor: 5.166

3.  The effects of continuing care on emerging adult outcomes following residential addiction treatment.

Authors:  Brandon G Bergman; Bettina B Hoeppner; Lindsay M Nelson; Valerie Slaymaker; John F Kelly
Journal:  Drug Alcohol Depend       Date:  2015-05-27       Impact factor: 4.492

4.  Demystifying buprenorphine misuse: Has fear of diversion gotten in the way of addressing the opioid crisis?

Authors:  Molly Doernberg; Noa Krawczyk; Deborah Agus; Michael Fingerhood
Journal:  Subst Abus       Date:  2019-04-22       Impact factor: 3.716

5.  Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2 years: Results from a multisite randomized trial of adults with opioid use disorder.

Authors:  Elizabeth A Evans; Caroline Yoo; David Huang; Andrew J Saxon; Yih-Ing Hser
Journal:  J Subst Abuse Treat       Date:  2019-08-07

Review 6.  Non-Opioid Treatments for Opioid Use Disorder: Rationales and Data to Date.

Authors:  Reda M Chalhoub; Peter W Kalivas
Journal:  Drugs       Date:  2020-10       Impact factor: 9.546

7.  It will end in tiers: A strategy to include "dabblers" in the buprenorphine workforce after the X-waiver.

Authors:  Brendan Saloner; Barbara Andraka Christou; Adam J Gordon; Bradley D Stein
Journal:  Subst Abus       Date:  2021-04-02       Impact factor: 3.716

Review 8.  Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders.

Authors:  Francisco Navarrete; María Salud García-Gutiérrez; Ani Gasparyan; Amaya Austrich-Olivares; Jorge Manzanares
Journal:  Front Pharmacol       Date:  2021-05-20       Impact factor: 5.810

Review 9.  Sleep abnormalities associated with alcohol, cannabis, cocaine, and opiate use: a comprehensive review.

Authors:  Gustavo A Angarita; Nazli Emadi; Sarah Hodges; Peter T Morgan
Journal:  Addict Sci Clin Pract       Date:  2016-04-26

10.  SCOPE of Pain: An Evaluation of an Opioid Risk Evaluation and Mitigation Strategy Continuing Education Program.

Authors:  Daniel P Alford; Lara Zisblatt; Pamela Ng; Sean M Hayes; Sophie Peloquin; Ilana Hardesty; Julie L White
Journal:  Pain Med       Date:  2016-01       Impact factor: 3.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.